Oral abstract presentations

In this session, three data presentations were given by clinicians and scientists:

One-time lonvoguran ziclumeran (lonvo-z) 50mg in patients with hereditary angioedema: Up to 3 years durability and safety update

Dr Padmalal Gurugama, from Cambridge University Hospitals in the United Kingdom, presented data on the use of the potential gene therapy for HAE, now known as lonvo-z. The data were from a pooled analysis of the 32 patients treated in a Phase 1/2 study. The study followed patients for up to three years, and the authors found deep, stable, and durable reductions in plasma kallikrein. The majority of patients became attack free and did not need to continue long-term prophylaxis, while no long-term safety risks were identified, and the medicine was well-tolerated.

Impact of HAE attack rates and health-related quality of life: Results from the ALPHA-STAR trial

Dr Anna Valerieva from the Medical University of Sofia in Bulgaria presented data from a clinical trial of navenibart (STAR-015), a potentially long-acting treatment for the prevention of HAE attacks. She showed an average reduction of at least 86% in the monthly attack rate compared to baseline, with quality of life improvements lasting at least six months. Most commonly reported side effects of the treatment were headache, nasal congestion, and urinary tract infections.

Results of the phase 2 CHAPTER-1 open-label extension study on the long-term safety and efficacy of oral deucrictibant for prophylaxis in hereditary angioedema 

Dr Emel Aygören-Pürsün from the Goethe University in Frankfurt, Germany, presented data on the long-term safety and efficacy of a potential new treatment called deucrictibant. She concluded that these data were the first evidence on the long-term safety and efficacy of deucrictibant, showing that the attack rate was reduced after the first week of treatment, and remained low for approximately 34 months. The overall average attack rate was 0.12 during the trial’s extension period, and approximately half of the patients were attack free over that time. The medicine was generally well tolerated, with no safety signals in laboratory tests.